PCOS / PMOS Treatment Finder
PCOS (Polycystic Ovary Syndrome), now also referred to as PMOS (Polycystic and Multi-follicular Ovary Syndrome) following the 2023 nomenclature update, is a heterogeneous condition: there is no single universal treatment. The right therapeutic approach depends on your phenotype, your most pressing symptoms, your life plans, and your blood work.
This interactive tool guides you through 7 steps to identify the treatments best suited to your profile, from the 9 most commonly prescribed or recommended options in PCOS / PMOS as of 2026. It is grounded in the ESHRE 2023 guidelines, national clinical frameworks, and recent peer-reviewed evidence.
Output: a personalised ranked list of treatments with indication, indicative dosage, expected benefits, and links to detailed profiles — exportable as a PDF to bring to your next appointment.
Step 1 — Main symptoms
Select all your current symptoms (multiple choices allowed).
How to use this tool
The tool unfolds over 7 progressive steps, each corresponding to a clinically relevant criterion in PCOS / PMOS treatment selection. You can go back at any time to revise your answers.
At step 5 (BMI), an integrated calculator lets you enter your weight and height if you do not know your body mass index. BMI is an important criterion because certain treatments — such as GLP-1 agonists or metformin dose adjustments — are more strongly indicated in cases of obesity or overweight.
If you do not know your phenotype, the tool provides a link to the phenotype quiz. If you are unsure whether you have insulin resistance, the HOMA-IR calculator is accessible from step 6. These companion tools will help you answer more accurately.
At the end of the questionnaire, treatments are ranked by relevance score. Each card can be expanded to reveal side effects, and you can add treatments to your personal shortlist. The “Download my treatment summary PDF” button generates a document to bring to your appointment.
Understanding the recommendations and discussing them with your doctor
The recommendations in this tool are grounded in the ESHRE 2023 guidelines(European Society of Human Reproduction and Embryology), widely regarded as the most comprehensive international reference for PCOS management. These guidelines clearly distinguish first-, second-, and third-line treatments according to clinical objectives.
For insulin resistance: metformin remains the reference medication, increasingly complemented by myo-inositol which offers a favourable tolerability profile. The combination of the two shows a synergistic effect in several randomised trials.
For hyperandrogenism (acne, hirsutism): combined oral contraceptives (COC) and spironolactone are the best-documented treatments. Spironolactone requires effective contraception due to its teratogenic risk. COC pills containing cyproterone acetate are contraindicated in patients with a history of meningioma.
For ovulation induction: letrozole is now recommended as first-line before clomiphene, with higher cumulative pregnancy rates and a more favourable mono-follicular profile. It requires ultrasound monitoring and strict medical follow-up.
For obesity: GLP-1 agonists (semaglutide, tirzepatide) show very encouraging preliminary results in PCOS with obesity. They do not hold a specific PCOS licence in most countries but are used in clinical practice at some specialist centres.
When you attend your appointment, present the generated PDF to your doctor. Ask specific questions: why this treatment and not another, what the alternatives are, how to measure efficacy and over what timeframe. Also refer to our guide to questions to ask your doctor to make the most of that conversation.
Frequently asked questions
Can this tool replace my doctor?
No. This tool is exclusively educational. It provides general guidance based on common clinical criteria in PCOS / PMOS, but does not account for your full medical history. Only a doctor can prescribe a treatment suited to your individual situation.
Is my data transmitted anywhere?
No. All answers and calculations are processed in your browser. No data is sent to our servers or any third party.
Why does metformin appear frequently in results?
Metformin is the most studied medication in PCOS with insulin resistance. It is recommended by ESHRE as first-line treatment in women with PCOS who have insulin resistance, obesity, or cycle disturbances. Its weight in the algorithm reflects current clinical guidelines (2023).
How is each treatment score calculated?
Each treatment receives points based on symptom match (+20 per matching symptom), objective match (+30), BMI match (+15), confirmed insulin resistance (+25), and phenotype fit (+10). Treatments incompatible with pregnancy lose 50 points if you are trying to conceive within 6 months. Contraindications permanently disqualify a treatment from the results.
Are GLP-1 agonists (Ozempic, Mounjaro) recommended for PCOS?
GLP-1 and GIP agonists show promising results in PCOS with obesity and insulin resistance, but do not yet hold a specific PCOS licence in most countries as of 2026. Prescriptions remain off-label for this indication. Clinical trials are ongoing. Discuss with your doctor whether this is relevant for your case.